Company intelligence / Profile preview

Medivir

Ownership: Public · MVIR B
Development stage: Phase 2

Overview

Medivir is developing innovative cancer treatments focusing on areas with high unmet medical need. The company has successfully developed two pharmaceutical products, Xerclear and Olysio, from idea to market launch[4].

Therapeutic areas: Oncology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

15 assets

birinapant

14 more assets in the full pipeline.

Request access →

Partnerships

Has ventured into more than 20 partnership agreements, often with repeat partners[4].Collaborates with academic and industrial partners[2].

Financials

Market cap: $42.1M
Total revenue: $0
Enterprise value: $-52.5M

Beyond the preview

Go deeper on Medivir.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Medivir.

Explore the full profile